tulmimetostat (DZR123) / Novartis 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Enrollment change, Trial completion date, Trial primary completion date:  FIH: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov) -  May 15, 2025   
    P1/2,  N=275, Recruiting, 
    Trial primary completion date: Jul 2026 --> Nov 2026 N=210 --> 275 | Trial completion date: Mar 2026 --> Feb 2030 | Trial primary completion date: Dec 2025 --> Feb 2030
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Trial completion date, Trial primary completion date, Platinum sensitive:  CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) -  Apr 18, 2025   
    P1,  N=30, Recruiting, 
    *Patients who received ?1 dose, had ?1 post-baseline response assessment, or discontinued treatment prior to first post-baseline assessment for any reason. Trial completion date: Aug 2028 --> Dec 2028 | Trial primary completion date: May 2025 --> Jul 2026
  • ||||||||||  Review, Journal, IO biomarker:  Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance. (Pubmed Central) -  Mar 6, 2025   
    Given PRC2's multifaceted role in cancer biology, its inhibition represents a promising avenue for therapeutic intervention. The continued development of PRC2 inhibitors and exploration of their use in combination with standard chemotherapy or immunotherapy has great potential for improving patient outcomes in cancers driven by PRC2 dysregulation.
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Trial completion date, Trial primary completion date, Platinum sensitive:  CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) -  Feb 11, 2025   
    P1,  N=30, Recruiting, 
    The continued development of PRC2 inhibitors and exploration of their use in combination with standard chemotherapy or immunotherapy has great potential for improving patient outcomes in cancers driven by PRC2 dysregulation. Trial completion date: Aug 2029 --> Aug 2028 | Trial primary completion date: Jan 2027 --> May 2025
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Trial completion date, Trial primary completion date:  EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Sep 19, 2024   
    P1/2,  N=66, Not yet recruiting, 
    Trial completion date: Aug 2029 --> Aug 2028 | Trial primary completion date: Jan 2027 --> May 2025 Trial completion date: Jun 2028 --> Oct 2028 | Trial primary completion date: Jun 2026 --> Oct 2026
  • ||||||||||  tulmimetostat (CPI-0209) / MorphoSys
    Journal:  Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. (Pubmed Central) -  Jun 4, 2024   
    Importantly, a tulmimetostat controlled gene expression signature identified in whole blood from a cohort of 32 cancer patients correlated with tulmimetostat exposure, representing a pharmacodynamic marker for the assessment of target coverage for PRC2-targeted agents in the clinic. Collectively, this data suggests that tulmimetostat has the potential to achieve clinical benefit in solid tumors as a monotherapy but also in combination with chemotherapeutic agents and may be beneficial in various indications with recurrent ARID1A mutations.
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Trial completion date, Trial primary completion date:  EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Apr 4, 2024   
    P1/2,  N=66, Not yet recruiting, 
    These preliminary findings in heavily pretreated pts with multiple tumor types and evolving dose-optimization data support ongoing investigation of tulmimetostat. Trial completion date: Apr 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2026
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Enrollment open, Trial primary completion date, Platinum sensitive:  CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) -  Jan 18, 2024   
    P1,  N=30, Recruiting, 
    Trial completion date: Apr 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2026 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Jan 2027
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Enrollment open:  Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and S (clinicaltrials.gov) -  Jan 11, 2024   
    P1,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Jan 2027 Not yet recruiting --> Recruiting
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Trial completion date, Trial initiation date, Trial primary completion date, Platinum sensitive:  CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) -  Nov 27, 2023   
    P1,  N=30, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jan 2029 --> Jul 2029 | Initiation date: Sep 2023 --> Dec 2023 | Trial primary completion date: Oct 2025 --> Dec 2027
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Trial completion date, Trial initiation date, Trial primary completion date:  Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and S (clinicaltrials.gov) -  Nov 8, 2023   
    P1,  N=30, Not yet recruiting, 
    Trial completion date: Jan 2029 --> Jul 2029 | Initiation date: Sep 2023 --> Dec 2023 | Trial primary completion date: Oct 2025 --> Dec 2027 Trial completion date: Sep 2029 --> Dec 2029 | Initiation date: Sep 2023 --> Dec 2023 | Trial primary completion date: Oct 2027 --> Jan 2028
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Trial completion date, Trial initiation date, Trial primary completion date:  EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Jan 26, 2023   
    P1/2,  N=66, Not yet recruiting, 
    These preliminary findings in heavily pretreated pts with multiple tumor types, including tumors with ARID1A alterations or BAP1 loss, support ongoing investigation of tulmimetostat. Trial completion date: Dec 2026 --> Apr 2027 | Initiation date: Jan 2023 --> May 2023 | Trial primary completion date: Jan 2025 --> May 2025
  • ||||||||||  tulmimetostat (DZR123) / Novartis
    Trial completion date, Trial initiation date, Trial primary completion date:  EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Oct 13, 2022   
    P1/2,  N=66, Not yet recruiting, 
    Trial completion date: Dec 2026 --> Apr 2027 | Initiation date: Jan 2023 --> May 2023 | Trial primary completion date: Jan 2025 --> May 2025 Trial completion date: Oct 2026 --> Dec 2026 | Initiation date: Oct 2022 --> Jan 2023 | Trial primary completion date: Apr 2025 --> Jan 2025
  • ||||||||||  CPI-0209 / Constellation
    [VIRTUAL] Therapeutic potential of CPI-0209 () -  Mar 11, 2021 - Abstract #AACR2021AACR_1912;    
    P1/2
    Transcriptomic analysis revealed that CPI-0209 treatment modulated both AR-related and AR-independent pathways, which reveals a potential mechanism to explain the synergy of CPI-0209 and AR inhibitors. Thus, our results indicate that CPI-0209 may have the potential to be effective for AR-dependent mCRPC that are resistant to current AR inhibitors, supporting potential clinical development in mCRPC.Keywords: EZH2, prostate cancer, epigenetics, resistant